Glecaprevir + Pibrentasvir: Efficacious, Safe for HCV After Liver Transplantation
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
All articles by Virginia Schad, PharmD
DAA Treatment Before Liver Transplantation May Improve Outcome
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
Benefits of Expanding HCV Treatment Outweigh Short-Term Costs for State Medicaid Programs
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
Progress Achieved in Hepatitis B Control in Western Pacific Region
Report describes progress made to achieve hepatitis B control in the Western Pacific Region and the steps taken to eliminate mother-to-child transmission of hepatitis B virus during 2005 to 2017.
A Global Meta-Analysis on HIV, HCV, and HBV in People Who Inject Drugs
Investigators assessed country, regional, and global incidence of serologically confirmed HIV, anti-hepatitis C virus, and hepatitis B virus prevalence according to gender in people who inject drugs.
Ledipasvir/Sofosbuvir ± Ribavirin Effective, Safe in HCV With Advanced Liver Disease
A combination treatment of ledipasvir/sofosbuvir with or without ribavirin was an effective and tolerable treatment in patients with chronic hepatitis C and advanced liver disease before and after liver transplantation.
Optimal Limit of Detection for a Point-of-Care HCV Viremia Test
Dataset of 66,640 individuals from 12 countries representative of 6 global regions confirmed that a test with a limit of detection of 1318 IU/mL would identify 97% of viremic HCV infections.
Ombitasvir/Paritaprevir/Ritonavir in Patients With HCV and Advanced Kidney Disease
Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin treatment was safe and effective in patients with stage 4 or 5 chronic kidney disease, hepatitis C.
Genetic Variants and Response to Peg Interferon in Chronic Hepatitis B
The current GWAS identified genetic variants that are associated with both short- and long-term responses to Peg IFN in patients with chronic hepatitis B.
Graft Survival After Liver Transplantation for Patients With HCV on Direct-Acting Antivirals
Despite being in the age range of their mid-fifties, patients with hepatitis C who have undergone liver transplants in a time period when direct-acting antivirals are available have fared similarly to liver transplant recipients without hepatitis C.
Next post in Hepatitis Advisor
